ISAL 2019 | Update on AMG 330 bispecific for R/R AML

Name: Update on AMG 330 bispecific for R/R AML
Uploaded: 2019-03-14T11:33:40.000Z
Duration: 1 min 38 s
Description: Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the preliminary pharmacokinetic data from the still-recruiting Phase I study of the bispecific CD3/CD33 antibody AMG 330 in relapsed/refractory acute myeloid leukemia (NCT02520427). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Marion Subklewe • 14 Mar 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Antibodies Eluvixtamab

Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the preliminary pharmacokinetic data from the still-recruiting Phase I study of the bispecific CD3/CD33 antibody AMG 330 in relapsed/refractory acute myeloid leukemia (NCT02520427). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.